[go: up one dir, main page]

US3173876A - Cleaning methods and compositions - Google Patents

Cleaning methods and compositions Download PDF

Info

Publication number
US3173876A
US3173876A US32088A US3208860A US3173876A US 3173876 A US3173876 A US 3173876A US 32088 A US32088 A US 32088A US 3208860 A US3208860 A US 3208860A US 3173876 A US3173876 A US 3173876A
Authority
US
United States
Prior art keywords
cleaning
compositions
ethylenediamine
composition
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US32088A
Inventor
John C Zobrist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US32088A priority Critical patent/US3173876A/en
Application granted granted Critical
Publication of US3173876A publication Critical patent/US3173876A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/26—Organic compounds containing nitrogen
    • C11D3/30—Amines; Substituted amines ; Quaternized amines

Definitions

  • compositions there are today two general types of composition in general use for the cleaning of Window glass, mirrors, bathroom tile, polished marble, and other highly reflective surfaces. These compositions may be roughly classified as household ammonias, that is, solutions of am monium hydroxide, and soap and detergent compositions. Each composition has undeniably useful properties for the proposed use, but each is also attended by certain inherent disadvantages.
  • Household ammonia or solutions of ammonium hy droxide have generally favorable cleaning activity, but this composition is highly odorous and irritating. This is especially a factor where the ammonium hydroxide solu tion is to be employed indoors, as is usually the case. For example, the average housewife finds the use of such compositions for window cleaning very unpleasant and the vapors may even result in irritation to the eyes and nose of the user to the point of causing headache and nausea in hypersensitive individuals.
  • soap and detergent compositions have come into use which have no noticeable or unpleasant odor.
  • soap or detergent compositions leave much to be desired.
  • soap and detergent solutions are generally effective to remove superficial soil from the surface to be cleaned, they invariably result in a streaked finish. This is occasioned by the fact that a thin film of the detergent material is generally left on the surface and appears in the form of visible streaks even though the surface has been wiped with a cloth following the application of the cleaner. It may be pointed out that the active ingredients in most of these soap and detergent type of cleaners are somewhat hygroscopic and have low vapor pressures.
  • a further object of the invention is the cleaning of highly reflective surfaces by means for aqueous composi- 3,173,876 Patented Mar. 16, 1965 tions which effectively remove from the surface all common varieties of soil, leave no streaks or residual film and are capable of use without unpleasant side effects, such as odor, skin irritation or the like.
  • Another object of the present invention is to provide compositions for the cleaning of highly reflective surfaces, especially glass, tile, marble, and like vitreous materials, which are capable of effectively removing greases, oils, gums and the other bases for the more common types of soil.
  • An additional object of the present invention is to provide cleaning compositions for use on the surface of glass, tile, and other vitreous or highly reflective surfaces which may be applied either by transfer from a saturated applicator or by spraying, which effectively clean and visibly brighten the treated surfaces and which may be employed without unpleasant odor, irritation or other undesirable side effects.
  • the present invention comprises treating highly reflective surfaces with an aqueous solution of ethylenediamine, the ethylenediamine being present in amounts of from 0.2 to 12%. It has been found that such solutions do not irritate, have no unpleasant odor, and will effectively clean highly polished or reflective surfaces Without streaking or depositing a residual film.
  • ethylcnediamine solutions may be attributed to the powerful solvent action which they have on greases and oils which are a principal component of many types of soil and which account in large part for residual streaking when treated with other cleaners.
  • Elhylcnediamine solutions also solubilize gums and saponify many fatty materials present in oils, converting them to highly soluble soaps which enhance the cleaning properties.
  • ethylenediamine has a vapor pressure that approaches that of water and, therefore, when applied in aqueous solution the ethylenediamine evaporates rapidly when compared to other solutions of soaps and detergents. This property accounts in some measure for the nonstreaking cleaning properties of aqueous cthylenediarnine solutions.
  • composition small but significant amounts, generally about 1.0% to 5.0% by volume, of an enhancing material, such as sodium borate, trisodium phosphate, sodium hexametaphosphate, sodium tripolyphosphate, and the like.
  • an enhancing material such as sodium borate, trisodium phosphate, sodium hexametaphosphate, sodium tripolyphosphate, and the like.
  • the concentration of cthylenediamine is between 3.0% and 10.0% by weight of the solution.
  • the enhancing substance will generally be present in amounts of from 1.0% to 5.0%.
  • the compositions may be used directly without further dilution.
  • the more concentrated solutions may be further diluted with water to a point where the concen' tration of ethylenediamine is from about 0.2% to 1.0%. The cleaning activity of the composition is still quite effective even at such a low concentration of the ethylenediamine.
  • compositions of the present invention lend themselves to a variety of types of application. According to more conventional practice, they maybe used to saturate an applicator, such as as absorbent cloth, and then are wiped upon the surface to be cleaned. After the elapse of a short period of time, generally only a few seconds, during which the ethylenediamine penetrates, dissolves and loosens soil, the surface may then be wiped clean with a dry cloth without leaving any streaks or residual film on the surface.
  • an applicator such as as absorbent cloth
  • aqueous solutions of ethylcnediamine may also be advantageously employed in spray application cleaning procedure by the addition of alcohol to promote more rapid drying.
  • alcohol for example, from 5.0% to 35.0% ethanol or isopropanol may be combined with an aqueous solution of ethylenediamine, with or without an enhancer, to produce a remarkably effective cleaner for use in spray application on glass, tile, marble or other highly reflective surfaces.
  • Example 1 [All formulae are expressed in percent by weight] Ethylcnediaminc 0.5 Water 99.5
  • Example 2 Ethylenediarnine 0.2 Sodium borate 0.2 ⁇ Vater 99.6
  • the cleaning compositions set forth in the above formulations are very useful for the cleaning of window panes and mirrors.
  • T he concentration of ethylenediamine is quite sufficient to remove ordinary surface S011 and after application from a cloth or other absorbent applicator the composition and entrained or dissolved soil may be completely removed from the surface by butting with a dry cloth without residual streaking.
  • composition of Formula No. 3 is quite satisfactory for heavy cleaning jobs and it is a composition of this approximate formula which is considered well suited for bottling and commercial sale.
  • the purchaser may use the composition in full strength or may dilute portions of the composition with water to obtain a reduced concentration of the ethylenediamine better suited to the particular need.
  • a composition of the above formula is especially suited to spray application to the surface to be cleaned.
  • such a composition might be introduced into one of the common, manually operated spray or atomizer bottles in wide use for applying cleaning materials to window glass.
  • compositions within the scope of the present invention and for use in methods for cleaning polished and reflective surfaces include the following:
  • compositions of the above Formulae 5, 6 and 7 are suited for wipoon, wipe-oil" application techniques.
  • compositions according to the Formulae 8, 9 and 10 are especially useful for spray-on, wipe-off methods of application.
  • compositions have been found to give excellent results and particular utility in the cleaning of polished vitreous surfaces, including ceramic tile, porcelain, window glass and the like.
  • highly polished or reflective surfaces such as those of glass, tile, marble and other like materials, may be efficiently and thoroughly cleaned by application of compositions of the type herein described, either by a wipe-on, wipe-off" mode of application or by a spray-on, wipe-off technique, and this is accomplished without odor, irritation or other un desirable side effects and without streaking or retention of: residual film on the cleaned surface.
  • the method for cleaning reflective vitreous surfaces which comprises applying to said surfaces a liquid composition consisting essentially of from 0.2% to 12.0% by Weight of ethylenediamine dissolved in water, and then removing said composition from said surface.
  • the method for cleaning reflective vitreous surfaces which comprises wiping onto said surfaces an aqueous solution consisting essentially of from 0.2% to 12.0% by weight ethylenediamine and from 0.2% to about 5.0% by weight of a material selected from the group consisting of sodium horate, trisodium phosphate, sodium hexametaphosphate and sodium tripolyphosphate, and then wiping said solution from said surfaces.
  • the method for cleaning reflective vitreous surfaces which comprises spraying onto said surfaces an aqueous solution consisting essentially of from 0.2% to 12.0% by weight cthylcnediarnine, and from 5.0% to 35.0% by weight of an alcohol selected from the group consisting of methanol, ethanol, propanol and isopropanol and then wiping said solution from said surfaces.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Detergent Compositions (AREA)

Description

United States Patent 3,173,876 CLEANING METHODS AND COMPOSITIONS John C. Zobl'ist, 1012 Bridge Road, Charleston 4, W. Ya. No Drawing. Filed May 27, 1960, Ser. No. 32,088 4 Claims. (Cl. 252-137) This invention relates to a method for cleaning highly reflective surfaces, especially glass, tile, marble, porcelain and other vitreous materials, and to compositions for use in such a method. More specifically, the present invention relates to a method for cleaning highly reflective or polished vitreous surfaces by the use of aqueous compositions containing ethylenediamine. This is a continuation-in-part of my copending application Serial No. 803,066 filed March 31, 1959, for Method for Cleaning Superficial Material From a Surface, now abandoned.
There are today two general types of composition in general use for the cleaning of Window glass, mirrors, bathroom tile, polished marble, and other highly reflective surfaces. These compositions may be roughly classified as household ammonias, that is, solutions of am monium hydroxide, and soap and detergent compositions. Each composition has undeniably useful properties for the proposed use, but each is also attended by certain inherent disadvantages.
Household ammonia or solutions of ammonium hy droxide have generally favorable cleaning activity, but this composition is highly odorous and irritating. This is especially a factor where the ammonium hydroxide solu tion is to be employed indoors, as is usually the case. For example, the average housewife finds the use of such compositions for window cleaning very unpleasant and the vapors may even result in irritation to the eyes and nose of the user to the point of causing headache and nausea in hypersensitive individuals.
Because of the disadvantages of the ammonium hydroxide cleaners, a number of soap and detergent compositions have come into use which have no noticeable or unpleasant odor. However, from the standpoint of cleaning action, such soap or detergent compositions leave much to be desired. While soap and detergent solutions are generally effective to remove superficial soil from the surface to be cleaned, they invariably result in a streaked finish. This is occasioned by the fact that a thin film of the detergent material is generally left on the surface and appears in the form of visible streaks even though the surface has been wiped with a cloth following the application of the cleaner. It may be pointed out that the active ingredients in most of these soap and detergent type of cleaners are somewhat hygroscopic and have low vapor pressures. These materials do not volatize readily after application and they draw from the air small amounts of moisture which result in very apparent streaking on the cleaned surface. Obviously, where the surface being cleaned is window glass, mirror glass, ceramic tiles or the like, the presence of streaking after cleaning is quite undesirable and actually defeats the purpose of the cleaning operation.
According to the present invention, there has been developed at method for cleaning highly reflective surfaces, especially vitreous surfaces such as glass, porcelain, tile and the like, which overcomes the noted disadvantages inherent in the use of other compositions known for such use.
It is, therefore, a primary object of this invention to provide a method for cleaning highly reflective surfaces which is not attended by the presence of strong or unpleasant odors and which does not result in streaking on the surface to be cleaned or retention by the surface of a residual film of cleaner.
A further object of the invention is the cleaning of highly reflective surfaces by means for aqueous composi- 3,173,876 Patented Mar. 16, 1965 tions which effectively remove from the surface all common varieties of soil, leave no streaks or residual film and are capable of use without unpleasant side effects, such as odor, skin irritation or the like.
Another object of the present invention is to provide compositions for the cleaning of highly reflective surfaces, especially glass, tile, marble, and like vitreous materials, which are capable of effectively removing greases, oils, gums and the other bases for the more common types of soil.
An additional object of the present invention is to provide cleaning compositions for use on the surface of glass, tile, and other vitreous or highly reflective surfaces which may be applied either by transfer from a saturated applicator or by spraying, which effectively clean and visibly brighten the treated surfaces and which may be employed without unpleasant odor, irritation or other undesirable side effects.
Broadly, the present invention comprises treating highly reflective surfaces with an aqueous solution of ethylenediamine, the ethylenediamine being present in amounts of from 0.2 to 12%. It has been found that such solutions do not irritate, have no unpleasant odor, and will effectively clean highly polished or reflective surfaces Without streaking or depositing a residual film.
The remarkable cleaning properties of ethylcnediamine solutions may be attributed to the powerful solvent action which they have on greases and oils which are a principal component of many types of soil and which account in large part for residual streaking when treated with other cleaners. Elhylcnediamine solutions also solubilize gums and saponify many fatty materials present in oils, converting them to highly soluble soaps which enhance the cleaning properties.
It should also be noted that ethylenediamine has a vapor pressure that approaches that of water and, therefore, when applied in aqueous solution the ethylenediamine evaporates rapidly when compared to other solutions of soaps and detergents. This property accounts in some measure for the nonstreaking cleaning properties of aqueous cthylenediarnine solutions.
It has also been found to be highly advantageous to introduce into the composition small but significant amounts, generally about 1.0% to 5.0% by volume, of an enhancing material, such as sodium borate, trisodium phosphate, sodium hexametaphosphate, sodium tripolyphosphate, and the like.
It has generally been found desirable to prepare solutions of the present type for commercial use wherein the concentration of cthylenediamine is between 3.0% and 10.0% by weight of the solution. In such formulation, the enhancing substance will generally be present in amounts of from 1.0% to 5.0%. Thus, if the accumulation of soil is especially heavy and a fairly concentrated cleaning solution is called for, the compositions may be used directly without further dilution. Also, for light cleaning jobs, the more concentrated solutions may be further diluted with water to a point where the concen' tration of ethylenediamine is from about 0.2% to 1.0%. The cleaning activity of the composition is still quite effective even at such a low concentration of the ethylenediamine.
The compositions of the present invention lend themselves to a variety of types of application. According to more conventional practice, they maybe used to saturate an applicator, such as as absorbent cloth, and then are wiped upon the surface to be cleaned. After the elapse of a short period of time, generally only a few seconds, during which the ethylenediamine penetrates, dissolves and loosens soil, the surface may then be wiped clean with a dry cloth without leaving any streaks or residual film on the surface.
By a slight modification the aqueous solutions of ethylcnediamine may also be advantageously employed in spray application cleaning procedure by the addition of alcohol to promote more rapid drying. For example, from 5.0% to 35.0% ethanol or isopropanol may be combined with an aqueous solution of ethylenediamine, with or without an enhancer, to produce a remarkably effective cleaner for use in spray application on glass, tile, marble or other highly reflective surfaces.
In order to better understand the present invention, it may be well to consider the following specific examples of preferred methods and compositions within the scope of the present invention:
Example 1 [All formulae are expressed in percent by weight] Ethylcnediaminc 0.5 Water 99.5 Example 2 Ethylenediarnine 0.2 Sodium borate 0.2 \Vater 99.6
The cleaning compositions set forth in the above formulations are very useful for the cleaning of window panes and mirrors. T he concentration of ethylenediamine is quite sufficient to remove ordinary surface S011 and after application from a cloth or other absorbent applicator the composition and entrained or dissolved soil may be completely removed from the surface by butting with a dry cloth without residual streaking.
Example 3 Ethylenediamine 7.0 Sodium phosphate 3.5 Water 89.5
The composition of Formula No. 3 is quite satisfactory for heavy cleaning jobs and it is a composition of this approximate formula which is considered well suited for bottling and commercial sale. The purchaser may use the composition in full strength or may dilute portions of the composition with water to obtain a reduced concentration of the ethylenediamine better suited to the particular need.
Example 4 Ethylenecliamine 0.2 Trisodium phosphate 0.2 Isopropanol 5.0 Water 94.6
A composition of the above formula is especially suited to spray application to the surface to be cleaned. For example, such a composition might be introduced into one of the common, manually operated spray or atomizer bottles in wide use for applying cleaning materials to window glass.
Other examples of compositions within the scope of the present invention and for use in methods for cleaning polished and reflective surfaces include the following:
Compositions of the above Formulae 5, 6 and 7 are suited for wipoon, wipe-oil" application techniques.
Example 8 Ethylenediamine 1.0 Sodium borate 1.0 Ethanol 10.0 Water 88.0
Example 9 Ethylenediamine 0.5 lsopropyl alcohol 20.0 Water 79.5
Example 10 Ethylenediamine 1.0 Trisodiun'i phosphate 1.0 Methyl alcohol 31.0 \Nater 63.0
Compositions according to the Formulae 8, 9 and 10 are especially useful for spray-on, wipe-off methods of application.
All of the foregoing compositions have been found to give excellent results and particular utility in the cleaning of polished vitreous surfaces, including ceramic tile, porcelain, window glass and the like.
According to the present invention, therefore, highly polished or reflective surfaces, such as those of glass, tile, marble and other like materials, may be efficiently and thoroughly cleaned by application of compositions of the type herein described, either by a wipe-on, wipe-off" mode of application or by a spray-on, wipe-off technique, and this is accomplished without odor, irritation or other un desirable side effects and without streaking or retention of: residual film on the cleaned surface.
It will be apparent to those skilled in the art that various modifications, changes, and substitutions may be made in the method and compositions comprising the present invention without materially departing from the scope of the invention and, therefore, the matter contained herein is intended to be illustrative rather than limitative.
What is claimed is:
1. The method for cleaning reflective vitreous surfaces which comprises applying to said surfaces a liquid composition consisting essentially of from 0.2% to 12.0% by Weight of ethylenediamine dissolved in water, and then removing said composition from said surface.
2. The method for cleaning reflective vitreous surfaces which comprises wiping onto said surfaces an aqueous solution consisting essentially of from 0.2% to 12.0% by weight ethylenediamine and from 0.2% to about 5.0% by weight of a material selected from the group consisting of sodium horate, trisodium phosphate, sodium hexametaphosphate and sodium tripolyphosphate, and then wiping said solution from said surfaces.
3. The method for cleaning reflective vitreous surfaces which comprises spraying onto said surfaces an aqueous solution consisting essentially of from 0.2% to 12.0% by weight cthylcnediarnine, and from 5.0% to 35.0% by weight of an alcohol selected from the group consisting of methanol, ethanol, propanol and isopropanol and then wiping said solution from said surfaces.
4. The method of claim 1 where said surface is glass.
References Cited by the Examiner UNITED STATES PATENTS 2,471,645 5/49 Morris et al. 252--l37 2,509,440 5/50 Little 252l37 2,524,380 10/50 Flaxman 252137 2,540,003 l/Sl McCoy 252l53 2,731,420 l/56 Sylvester 252l37 OTHER REFERENCES New Aliphatic Amines, article in Ind. and Eng. Chem., August 1935, vol. 27, No. 8, pages 867-871, by Wilson.
Surface Active Agents, by Schwartz et al., 1949, Interscience Pub, Inc, page 377.
JULIUS GREENWALD, Primary Examiner.

Claims (1)

  1. 2. THE METHOD FOR CLEANING REFLECTIVE VITREOUS SURFACES WHICH COMPRISES WIPING ONTO SAID SURFACES AN AQUEOUS SOLUTION CONSISTING ESSENTIALLY OF FROM 0.2% TO 12.0% BY WEIGHT ETHYLENEDIAMINE AND FROM 0.2% TO ABOUT 5.0% BY WEIGHT OF A MATERIAL SELECTED FROM THE GROUP CONSISTING OF SODIUM BORATE, TRISODIUM PHOSPHATE, SODIUM HEXAMETAPHOSPHATE AND SODIUM TRIPOLYPHOSPHATE, AND THEN WIPING SAID SOLUTION FROM SAID SURFACES.
US32088A 1960-05-27 1960-05-27 Cleaning methods and compositions Expired - Lifetime US3173876A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US32088A US3173876A (en) 1960-05-27 1960-05-27 Cleaning methods and compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32088A US3173876A (en) 1960-05-27 1960-05-27 Cleaning methods and compositions

Publications (1)

Publication Number Publication Date
US3173876A true US3173876A (en) 1965-03-16

Family

ID=21863034

Family Applications (1)

Application Number Title Priority Date Filing Date
US32088A Expired - Lifetime US3173876A (en) 1960-05-27 1960-05-27 Cleaning methods and compositions

Country Status (1)

Country Link
US (1) US3173876A (en)

Cited By (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321407A (en) * 1964-07-02 1967-05-23 Rosenfeld Myer Ethylenediamine-tetrahydrofuran paint-stripping compositions
US3322677A (en) * 1964-07-02 1967-05-30 Rosenfeld Myer Ethylenediamine-anisole paint-stripping compositions
US3324037A (en) * 1964-07-02 1967-06-06 Rosenfeld Myer Thixotropic ethylenediamine-based paint strippers
US3324039A (en) * 1964-07-02 1967-06-06 Rosenfeld Myer Ethylenediamine-n, n-dimethylformamide paint-stripping compositions
US3637508A (en) * 1970-03-06 1972-01-25 William B Willsey Process and composition for dissolving copper oxide
US4152306A (en) * 1976-02-26 1979-05-01 LDMJ Limited Windshield cleaning solvent
US4213873A (en) * 1978-03-10 1980-07-22 Leisure Products Corporation Water based window, glass and chrome cleaner composition
US4556509A (en) * 1984-10-09 1985-12-03 Colgate-Palmolive Company Light duty detergents containing an organic diamine diacid salt
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5252245A (en) * 1992-02-07 1993-10-12 The Clorox Company Reduced residue hard surface cleaner
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5468423A (en) * 1992-02-07 1995-11-21 The Clorox Company Reduced residue hard surface cleaner
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5523024A (en) * 1992-02-07 1996-06-04 The Clorox Company Reduced residue hard surface cleaner
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5707663A (en) * 1993-05-28 1998-01-13 Alza Corporation Sustained antiepileptic therapy
US5817615A (en) * 1992-02-07 1998-10-06 The Clorox Company Reduced residue hard surface cleaner
US5851981A (en) * 1995-03-24 1998-12-22 The Clorox Company Reduced residue hard surface cleaner
US5990065A (en) * 1996-12-20 1999-11-23 The Procter & Gamble Company Dishwashing detergent compositions containing organic diamines for improved grease cleaning, sudsing, low temperature stability and dissolution
WO2000023663A1 (en) 1998-10-21 2000-04-27 Reckitt Benckiser (Uk) Limited Dispensing device
US6069122A (en) * 1997-06-16 2000-05-30 The Procter & Gamble Company Dishwashing detergent compositions containing organic diamines for improved grease cleaning, sudsing, low temperature stability and dissolution
WO2000062764A1 (en) 1999-04-20 2000-10-26 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6210712B1 (en) 1997-12-05 2001-04-03 Alza Corporation Dosage form having first and second coats
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US20010038856A1 (en) * 1994-07-07 2001-11-08 Sonya Merrill Hydromorphone therapy
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20020048600A1 (en) * 1998-11-02 2002-04-25 Padmanabh Bhatt Controlled delivery of active agents
US20020058673A1 (en) * 1997-12-22 2002-05-16 Kaiko Robert F. Opioid agonist/opioid antagonist/acetaminophen combinations
US20020071863A1 (en) * 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US20030125714A1 (en) * 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
US6589926B1 (en) 1998-06-02 2003-07-08 Procter & Gamble Company Dishwashing detergent compositions containing organic diamines
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030198619A1 (en) * 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030232078A1 (en) * 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
US20030232082A1 (en) * 2001-09-28 2003-12-18 Shun-Por Li Modified release dosage forms
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US6727212B2 (en) 1997-11-10 2004-04-27 The Procter & Gamble Company Method for softening soil on hard surfaces
US20040086561A1 (en) * 1997-12-22 2004-05-06 Kaiko Robert F. Opioid agonist / antagonist combinations
US20040091529A1 (en) * 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US20040166160A1 (en) * 2003-01-14 2004-08-26 Ramkumar Subramanian Methods and dosage forms with modified viscosity layers
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050063909A1 (en) * 2001-08-06 2005-03-24 Euro-Celtique, S.A. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20050089570A1 (en) * 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20050112195A1 (en) * 2003-09-26 2005-05-26 Evangeline Cruz Drug coating providing high drug loading and methods for providing same
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
US20050148594A1 (en) * 2002-12-17 2005-07-07 Cink Russell D. Salts of fenofibric acid and pharmaceutical formulations thereof
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050192309A1 (en) * 1997-12-22 2005-09-01 Palermo Philip J. Method of preventing abuse of opioid dosage forms
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050222188A1 (en) * 2004-03-30 2005-10-06 Euro-Celtique S.A. Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050245483A1 (en) * 2002-04-05 2005-11-03 Bianca Brogmann Matrix for sustained, invariant and independent release of active compounds
US20050276850A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Controlled release sodium valproate formulation
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287212A1 (en) * 2004-06-28 2005-12-29 Liang-Chang Dong Oral delivery system comprising a drug/polymer complex
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US20060057206A1 (en) * 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060134196A1 (en) * 2002-12-17 2006-06-22 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
US20060193877A1 (en) * 2005-02-28 2006-08-31 Pfab, Lp Compositions and methods of making sustained release liquid formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2007053698A2 (en) 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20070128279A1 (en) * 1998-03-06 2007-06-07 Alza Corporation Extended Release Dosage Form
US20070259014A1 (en) * 2003-06-20 2007-11-08 Vgx Pharmaceuticals, Inc. Compositions for and Methods for Treating Hiv
US20070259045A1 (en) * 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
US20070281018A1 (en) * 2004-09-24 2007-12-06 Abbott Laboratories Sustained release formulations of opioid and nonopioid analgesics
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
EP1905435A2 (en) 2003-03-11 2008-04-02 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
WO2008084698A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Tacrolimus sustained release pharmaceutical composition
EP1961421A1 (en) 2004-06-08 2008-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US20080214629A1 (en) * 2007-02-09 2008-09-04 Scott Bull Controlled release compositions of tizanidine
EP2011485A2 (en) 2001-05-02 2009-01-07 Euro-Celtique S.A. Once-a-day oxycodone formulations
US20090011027A1 (en) * 2007-05-30 2009-01-08 Neos Therapeutics, Lp Modifying Drug Release in Suspensions of Ionic Resin Systems
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090081287A1 (en) * 2001-08-06 2009-03-26 Purdue Pharma L.P. Pharmaceutical Composition Containing Gelling Agent
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
EP2074992A1 (en) 2005-04-08 2009-07-01 Abbott Laboratories Pharmaceutical formulations
US20090169626A1 (en) * 2006-01-27 2009-07-02 Euro-Celtique S.A. Tamper resistant dosage forms
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US7736668B2 (en) 1991-06-27 2010-06-15 Janssen Pharmaceutica Nv System for delaying drug delivery up to seven hours
US20100152147A1 (en) * 2004-11-24 2010-06-17 Meda Pharmaceuticals Inc. Compositions Comprising Azelastine and Methods of Use Thereof
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100189782A1 (en) * 2007-03-02 2010-07-29 Gul Balwani Compositions Comprising Carisoprodol and Methods of Use Thereof
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition
EP2255808A2 (en) 2004-06-08 2010-12-01 Euro-Celtique S.A. Opioids for the treatment of the restlessness of the lower limbs
EP2298303A1 (en) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20110172259A1 (en) * 2005-02-28 2011-07-14 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
WO2011122524A1 (en) 2010-03-29 2011-10-06 アステラス製薬株式会社 Controlled release pharmaceutical composition
WO2014013313A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
WO2014013311A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
WO2014170755A2 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
WO2014179453A1 (en) 2013-04-30 2014-11-06 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
WO2015107471A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxycodone synthesis
WO2015107472A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxymorphone synthesis
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
EP2965753A1 (en) 2004-12-03 2016-01-13 Osmotica Kereskedelmi És Szolgáltató Kft Osmotic device containing amantadine and an osmotic salt
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
WO2016134846A1 (en) 2015-02-27 2016-09-01 Rottapharm Ltd. Composition for the treatment of acne
WO2016166732A1 (en) 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
WO2017008909A1 (en) 2015-07-16 2017-01-19 Rottapharm S. P. A. Oral formulation comprising berberine and morus alba extract
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10206891B2 (en) 2012-11-02 2019-02-19 Murray And Poole Enterprises Ltd Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
WO2019149884A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2021029430A1 (en) 2019-08-13 2021-02-18 大塚製薬株式会社 Oral pharmaceutical composition containing heterocyclic compound
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
WO2021252741A1 (en) 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Cited By (358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321407A (en) * 1964-07-02 1967-05-23 Rosenfeld Myer Ethylenediamine-tetrahydrofuran paint-stripping compositions
US3322677A (en) * 1964-07-02 1967-05-30 Rosenfeld Myer Ethylenediamine-anisole paint-stripping compositions
US3324037A (en) * 1964-07-02 1967-06-06 Rosenfeld Myer Thixotropic ethylenediamine-based paint strippers
US3324039A (en) * 1964-07-02 1967-06-06 Rosenfeld Myer Ethylenediamine-n, n-dimethylformamide paint-stripping compositions
US3637508A (en) * 1970-03-06 1972-01-25 William B Willsey Process and composition for dissolving copper oxide
US4152306A (en) * 1976-02-26 1979-05-01 LDMJ Limited Windshield cleaning solvent
US4213873A (en) * 1978-03-10 1980-07-22 Leisure Products Corporation Water based window, glass and chrome cleaner composition
US4556509A (en) * 1984-10-09 1985-12-03 Colgate-Palmolive Company Light duty detergents containing an organic diamine diacid salt
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5312389A (en) * 1990-10-29 1994-05-17 Felix Theeuwes Osmotically driven syringe with programmable agent delivery
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US7736668B2 (en) 1991-06-27 2010-06-15 Janssen Pharmaceutica Nv System for delaying drug delivery up to seven hours
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5437807A (en) * 1992-02-07 1995-08-01 The Clorox Company Reduced residue hard surface cleaner
US5468423A (en) * 1992-02-07 1995-11-21 The Clorox Company Reduced residue hard surface cleaner
US5523024A (en) * 1992-02-07 1996-06-04 The Clorox Company Reduced residue hard surface cleaner
US5252245A (en) * 1992-02-07 1993-10-12 The Clorox Company Reduced residue hard surface cleaner
US5817615A (en) * 1992-02-07 1998-10-06 The Clorox Company Reduced residue hard surface cleaner
US20070009600A1 (en) * 1993-05-27 2007-01-11 Edgren David E Antidepressant dosage form
US20040092601A1 (en) * 1993-05-27 2004-05-13 Edgren David Emil Antidepressant dosage form
US20040086570A1 (en) * 1993-05-27 2004-05-06 Edgren David Emil Antidepressant dosage form
US8084059B2 (en) 1993-05-27 2011-12-27 Alza Corporation Antidepressant dosage form
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5980943A (en) * 1993-05-28 1999-11-09 Alza Corporation Sustained antiepileptic therapy
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5707663A (en) * 1993-05-28 1998-01-13 Alza Corporation Sustained antiepileptic therapy
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5603954A (en) * 1994-01-18 1997-02-18 Alza Corporation Pentoxifylline therapy and method of use
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US20100028389A1 (en) * 1994-07-07 2010-02-04 Sonya Merrill Hydromorphone therapy
US20010038856A1 (en) * 1994-07-07 2001-11-08 Sonya Merrill Hydromorphone therapy
US5851981A (en) * 1995-03-24 1998-12-22 The Clorox Company Reduced residue hard surface cleaner
US5990065A (en) * 1996-12-20 1999-11-23 The Procter & Gamble Company Dishwashing detergent compositions containing organic diamines for improved grease cleaning, sudsing, low temperature stability and dissolution
US6069122A (en) * 1997-06-16 2000-05-30 The Procter & Gamble Company Dishwashing detergent compositions containing organic diamines for improved grease cleaning, sudsing, low temperature stability and dissolution
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US6727212B2 (en) 1997-11-10 2004-04-27 The Procter & Gamble Company Method for softening soil on hard surfaces
US6210712B1 (en) 1997-12-05 2001-04-03 Alza Corporation Dosage form having first and second coats
US7419686B2 (en) 1997-12-22 2008-09-02 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US20100291203A1 (en) * 1997-12-22 2010-11-18 Purdue Pharma L.P. Opioid Agonist/Antagonist Combinations
US20050192309A1 (en) * 1997-12-22 2005-09-01 Palermo Philip J. Method of preventing abuse of opioid dosage forms
US8105631B2 (en) 1997-12-22 2012-01-31 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US9474750B2 (en) 1997-12-22 2016-10-25 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US7172767B2 (en) 1997-12-22 2007-02-06 Purdue Pharma L.P. Opioid agonist / antagonist combinations
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US20070122348A1 (en) * 1997-12-22 2007-05-31 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8936808B1 (en) 1997-12-22 2015-01-20 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US20080292694A1 (en) * 1997-12-22 2008-11-27 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US7749542B2 (en) 1997-12-22 2010-07-06 Purdue Pharma Lp Opioid agonist/antagonist combinations
US20040086561A1 (en) * 1997-12-22 2004-05-06 Kaiko Robert F. Opioid agonist / antagonist combinations
US20020058673A1 (en) * 1997-12-22 2002-05-16 Kaiko Robert F. Opioid agonist/opioid antagonist/acetaminophen combinations
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US20070128279A1 (en) * 1998-03-06 2007-06-07 Alza Corporation Extended Release Dosage Form
US6589926B1 (en) 1998-06-02 2003-07-08 Procter & Gamble Company Dishwashing detergent compositions containing organic diamines
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US20080181944A1 (en) * 1998-09-08 2008-07-31 Alza Corporation Dosage Form Comprising Therapeutic Formulation
US20030157163A1 (en) * 1998-09-08 2003-08-21 Liang-Chang Dong Dosage form comprising therapeutic formulation
US20100159002A1 (en) * 1998-09-08 2010-06-24 Liang-Chang Dong Dosage form comprising therapeutic formulation
US20090130204A1 (en) * 1998-09-08 2009-05-21 Encinal Pharmaceutical Investment Inc. Dosage Form Comprising Therapeutic Formulation
US6510561B1 (en) 1998-10-21 2003-01-28 Reckitt Benckiser (Uk) Limited Dispensing device
WO2000023663A1 (en) 1998-10-21 2000-04-27 Reckitt Benckiser (Uk) Limited Dispensing device
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
EP1652516A2 (en) 1998-11-02 2006-05-03 ALZA Corporation Osmotic controlled delivery of active agents
US20020048600A1 (en) * 1998-11-02 2002-04-25 Padmanabh Bhatt Controlled delivery of active agents
US6855334B2 (en) 1998-11-02 2005-02-15 Alta Corporation Controlled delivery of active agents
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6596314B2 (en) 1998-12-23 2003-07-22 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2000062764A1 (en) 1999-04-20 2000-10-26 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US20020071863A1 (en) * 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP3146963A1 (en) 2001-05-02 2017-03-29 Euro-Celtique S.A. Once-a-day oxycodone formulations
EP2011485A2 (en) 2001-05-02 2009-01-07 Euro-Celtique S.A. Once-a-day oxycodone formulations
US9480685B2 (en) 2001-05-11 2016-11-01 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9056051B2 (en) 2001-05-11 2015-06-16 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9084729B2 (en) 2001-05-11 2015-07-21 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9161937B2 (en) 2001-05-11 2015-10-20 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9168252B2 (en) 2001-05-11 2015-10-27 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283221B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283216B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9345701B1 (en) 2001-05-11 2016-05-24 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9358230B1 (en) 2001-05-11 2016-06-07 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9511066B2 (en) 2001-05-11 2016-12-06 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US8337888B2 (en) 2001-08-06 2012-12-25 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8999961B2 (en) 2001-08-06 2015-04-07 Purdue Pharma, L.P. Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20060182801A1 (en) * 2001-08-06 2006-08-17 Christopher Breder Sequestered antagonist formulations
US9517207B2 (en) 2001-08-06 2016-12-13 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9387173B2 (en) 2001-08-06 2016-07-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9387174B2 (en) 2001-08-06 2016-07-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10206881B2 (en) 2001-08-06 2019-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10130586B2 (en) 2001-08-06 2018-11-20 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10076497B2 (en) 2001-08-06 2018-09-18 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10071057B2 (en) 2001-08-06 2018-09-11 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064825B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9308171B2 (en) 2001-08-06 2016-04-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9308170B2 (en) 2001-08-06 2016-04-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9693961B2 (en) 2001-08-06 2017-07-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9757341B2 (en) 2001-08-06 2017-09-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
USRE45822E1 (en) 2001-08-06 2015-12-22 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US9861582B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9861583B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064824B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20050063909A1 (en) * 2001-08-06 2005-03-24 Euro-Celtique, S.A. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US9060976B2 (en) 2001-08-06 2015-06-23 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9044435B2 (en) 2001-08-06 2015-06-02 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9040084B2 (en) 2001-08-06 2015-05-26 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9034376B2 (en) 2001-08-06 2015-05-19 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US7384653B2 (en) 2001-08-06 2008-06-10 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US11135171B2 (en) 2001-08-06 2021-10-05 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20100168148A1 (en) * 2001-08-06 2010-07-01 Curtis Wright Pharmaceutical formulation containing gelling agent
US9867784B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9867783B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8871265B2 (en) 2001-08-06 2014-10-28 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9872836B2 (en) 2001-08-06 2018-01-23 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8389007B2 (en) 2001-08-06 2013-03-05 Purdue Pharma L.P. Pharmaceutical composition containing gelling agent
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US9968559B2 (en) 2001-08-06 2018-05-15 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9877924B2 (en) 2001-08-06 2018-01-30 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10537526B2 (en) 2001-08-06 2020-01-21 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8758825B2 (en) 2001-08-06 2014-06-24 Purdue Pharma L.P. Sequestered antagonist formulations
US8529948B1 (en) 2001-08-06 2013-09-10 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20090081287A1 (en) * 2001-08-06 2009-03-26 Purdue Pharma L.P. Pharmaceutical Composition Containing Gelling Agent
US10500160B2 (en) 2001-08-06 2019-12-10 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8609683B2 (en) 2001-08-06 2013-12-17 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20030232082A1 (en) * 2001-09-28 2003-12-18 Shun-Por Li Modified release dosage forms
US20070207204A1 (en) * 2001-12-18 2007-09-06 Alza Corporation Dosage Form for Time-Varying Patterns of Drug Delivery
US20030125714A1 (en) * 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
US20030198619A1 (en) * 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030232078A1 (en) * 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
US20050245483A1 (en) * 2002-04-05 2005-11-03 Bianca Brogmann Matrix for sustained, invariant and independent release of active compounds
US10420762B2 (en) 2002-04-05 2019-09-24 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US20050245556A1 (en) * 2002-04-05 2005-11-03 Bianca Brogmann Pharmaceutical preparation containing oxycodone and naloxone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
US20040091529A1 (en) * 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20090202631A1 (en) * 2002-07-29 2009-08-13 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US20060134196A1 (en) * 2002-12-17 2006-06-22 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20050148594A1 (en) * 2002-12-17 2005-07-07 Cink Russell D. Salts of fenofibric acid and pharmaceutical formulations thereof
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20040166160A1 (en) * 2003-01-14 2004-08-26 Ramkumar Subramanian Methods and dosage forms with modified viscosity layers
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
EP1905435A2 (en) 2003-03-11 2008-04-02 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US10092519B2 (en) 2003-04-21 2018-10-09 Purdue Pharma L.P. Pharmaceutical products
US20070259014A1 (en) * 2003-06-20 2007-11-08 Vgx Pharmaceuticals, Inc. Compositions for and Methods for Treating Hiv
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
EP2298303A1 (en) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20050089570A1 (en) * 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
US8226979B2 (en) 2003-09-26 2012-07-24 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20050112195A1 (en) * 2003-09-26 2005-05-26 Evangeline Cruz Drug coating providing high drug loading and methods for providing same
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20080206337A1 (en) * 2004-03-05 2008-08-28 Hai Yong Huang Method of making dosage forms comprising polymeric compositions
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20100152449A1 (en) * 2004-03-30 2010-06-17 Purdue Pharma Lp 8a,14-DIHYDROXY-7,8-DIHYDROCODEINONE
US7683072B2 (en) 2004-03-30 2010-03-23 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US9073933B2 (en) 2004-03-30 2015-07-07 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
EP2314589A1 (en) 2004-03-30 2011-04-27 Euro-Celtique S.A. Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
US10259819B2 (en) 2004-03-30 2019-04-16 Purdue Pharma L.P. Process for preparing oxycodone compositions
US7129248B2 (en) 2004-03-30 2006-10-31 Euro-Celtique, S.A. Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US11384091B2 (en) 2004-03-30 2022-07-12 Purdue Pharma L.P. Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US11236098B2 (en) 2004-03-30 2022-02-01 Purdue Pharma L.P. Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US10407434B2 (en) 2004-03-30 2019-09-10 Purdue Pharma L.P. Process for preparing oxycodone compositions
US20070117830A1 (en) * 2004-03-30 2007-05-24 Euro-Celtique S.A. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US20070117831A1 (en) * 2004-03-30 2007-05-24 Euro-Celtique S.A. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US7674799B2 (en) 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US12060361B2 (en) 2004-03-30 2024-08-13 Purdue Pharma L.P. Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US20070117829A1 (en) * 2004-03-30 2007-05-24 Euro-Celtique S.A. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
EP2311839A1 (en) 2004-03-30 2011-04-20 Euro-Celtique S.A. Oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone
US9522919B2 (en) 2004-03-30 2016-12-20 Purdue Pharma L.P. Oxycodone compositions
US8822687B2 (en) 2004-03-30 2014-09-02 Purdue Pharma L.P. 8a,14-dihydroxy-7,8-dihydrocodeinone
US20090227615A1 (en) * 2004-03-30 2009-09-10 Purdue Pharma Lp Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US10689389B2 (en) 2004-03-30 2020-06-23 Purdue Pharma L.P. Process for preparing oxycodone compositions
US7674800B2 (en) 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
US7674798B2 (en) 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
EP2316837A1 (en) 2004-03-30 2011-05-04 Euro-Celtique S.A. Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
US20050222188A1 (en) * 2004-03-30 2005-10-06 Euro-Celtique S.A. Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
US20070179169A1 (en) * 2004-03-30 2007-08-02 Euro-Celtique S.A. Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
EP2305683A1 (en) 2004-03-30 2011-04-06 Euro-Celtique S.A. Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US9777011B2 (en) 2004-03-30 2017-10-03 Purdue Pharma L.P. Process for preparing oxycodone compositions
US10696684B2 (en) 2004-03-30 2020-06-30 Purdue Pharma L.P. Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
EP2426132A1 (en) 2004-03-30 2012-03-07 Euro-Celtique S.A. Process for preparing 14-hydroxycodeinone from thebaine
EP2319846A1 (en) 2004-03-30 2011-05-11 Euro-Celtique S.A. Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP2255808A2 (en) 2004-06-08 2010-12-01 Euro-Celtique S.A. Opioids for the treatment of the restlessness of the lower limbs
EP1961421A1 (en) 2004-06-08 2008-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US10525052B2 (en) 2004-06-12 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20050276850A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Controlled release sodium valproate formulation
US7713550B2 (en) 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US20050287212A1 (en) * 2004-06-28 2005-12-29 Liang-Chang Dong Oral delivery system comprising a drug/polymer complex
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form
US20060057206A1 (en) * 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US20070281018A1 (en) * 2004-09-24 2007-12-06 Abbott Laboratories Sustained release formulations of opioid and nonopioid analgesics
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP2377557A2 (en) 2004-11-24 2011-10-19 MedPointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8518919B2 (en) 2004-11-24 2013-08-27 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2486942A1 (en) 2004-11-24 2012-08-15 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2522365A1 (en) 2004-11-24 2012-11-14 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
US20100152147A1 (en) * 2004-11-24 2010-06-17 Meda Pharmaceuticals Inc. Compositions Comprising Azelastine and Methods of Use Thereof
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8071073B2 (en) 2004-11-24 2011-12-06 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2965753A1 (en) 2004-12-03 2016-01-13 Osmotica Kereskedelmi És Szolgáltató Kft Osmotic device containing amantadine and an osmotic salt
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
US20070259045A1 (en) * 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
US20110172259A1 (en) * 2005-02-28 2011-07-14 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US9522120B2 (en) 2005-02-28 2016-12-20 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20060193877A1 (en) * 2005-02-28 2006-08-31 Pfab, Lp Compositions and methods of making sustained release liquid formulations
US20110237675A1 (en) * 2005-04-08 2011-09-29 Abbott Laboratories Pharmaceutical formulations
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
EP2074992A1 (en) 2005-04-08 2009-07-01 Abbott Laboratories Pharmaceutical formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
US20090221621A1 (en) * 2005-10-31 2009-09-03 Alza Corporation Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
WO2007053698A2 (en) 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090169626A1 (en) * 2006-01-27 2009-07-02 Euro-Celtique S.A. Tamper resistant dosage forms
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
WO2008084698A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Tacrolimus sustained release pharmaceutical composition
US8524749B2 (en) 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
US20080214629A1 (en) * 2007-02-09 2008-09-04 Scott Bull Controlled release compositions of tizanidine
US20100189782A1 (en) * 2007-03-02 2010-07-29 Gul Balwani Compositions Comprising Carisoprodol and Methods of Use Thereof
US8895061B2 (en) 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US8313770B2 (en) 2007-05-30 2012-11-20 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US20090011027A1 (en) * 2007-05-30 2009-01-08 Neos Therapeutics, Lp Modifying Drug Release in Suspensions of Ionic Resin Systems
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
EP3045043A1 (en) 2009-02-26 2016-07-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20100260859A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011122524A1 (en) 2010-03-29 2011-10-06 アステラス製薬株式会社 Controlled release pharmaceutical composition
US10966932B2 (en) 2010-12-22 2021-04-06 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9872837B2 (en) 2010-12-22 2018-01-23 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US20160158158A1 (en) 2010-12-22 2016-06-09 Purdue Pharma L.P. Encased Tamper Resistant Controlled Release Dosage Forms
US11590082B2 (en) 2010-12-22 2023-02-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11911512B2 (en) 2010-12-22 2024-02-27 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9861584B2 (en) 2010-12-22 2018-01-09 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9744136B2 (en) 2010-12-22 2017-08-29 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9750703B2 (en) 2010-12-22 2017-09-05 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9895317B2 (en) 2010-12-23 2018-02-20 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US10202396B2 (en) 2012-07-16 2019-02-12 Rhodes Technologies Process for improved opioid synthesis
WO2014013313A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
US10316042B2 (en) 2012-07-16 2019-06-11 Rhodes Technologies Process for improved opioid synthesis
WO2014013311A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
US11390627B2 (en) 2012-07-16 2022-07-19 Rhodes Technologies Process for improved opioid synthesis
US11944594B2 (en) 2012-11-02 2024-04-02 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11026899B2 (en) 2012-11-02 2021-06-08 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11666545B2 (en) 2012-11-02 2023-06-06 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10206891B2 (en) 2012-11-02 2019-02-19 Murray And Poole Enterprises Ltd Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
US11026901B2 (en) 2012-11-02 2021-06-08 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11944595B2 (en) 2012-11-02 2024-04-02 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10842761B2 (en) 2012-11-02 2020-11-24 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10265281B2 (en) 2012-11-02 2019-04-23 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10842762B2 (en) 2012-11-02 2020-11-24 Murray And Poole Enterprises Ltd Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
US11026900B2 (en) 2012-11-02 2021-06-08 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9662399B2 (en) 2013-02-05 2017-05-30 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9545448B2 (en) 2013-02-05 2017-01-17 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10478504B2 (en) 2013-02-05 2019-11-19 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US11576974B2 (en) 2013-02-05 2023-02-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations
US9655971B2 (en) 2013-02-05 2017-05-23 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10792364B2 (en) 2013-02-05 2020-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10517832B2 (en) 2013-03-15 2019-12-31 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10195152B2 (en) 2013-03-15 2019-02-05 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10610488B2 (en) 2013-04-16 2020-04-07 Murray & Poole Enterprises, Ltd. Sustained-release formulations of colchicine and methods of using same
US11648206B2 (en) 2013-04-16 2023-05-16 Murray And Poole Enterprises Ltd Sustained-release formulations of colchicine and methods of using same
WO2014170755A2 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US10130585B2 (en) 2013-04-16 2018-11-20 Murray And Poole Enterprises Limited Methods of treating and/or preventing cardiovascular disease
US10105319B2 (en) 2013-04-16 2018-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
WO2014179453A1 (en) 2013-04-30 2014-11-06 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9932348B2 (en) 2014-01-15 2018-04-03 Rhodes Technologies Process for improved oxycodone synthesis
US10428079B2 (en) 2014-01-15 2019-10-01 Rhodes Technologies Process for improved oxycodone synthesis
US9938285B2 (en) 2014-01-15 2018-04-10 Rhodes Technologies Process for improved oxymorphone synthesis
US10189852B2 (en) 2014-01-15 2019-01-29 Rhodes Technologies Process for improved oxymorphone synthesis
WO2015107471A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxycodone synthesis
WO2015107472A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxymorphone synthesis
US10844072B2 (en) 2014-01-15 2020-11-24 Rhodes Technologies Process for improved oxycodone synthesis
WO2016132218A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of administering r-baclofen in an extended release dosage form
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
WO2016132220A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist
WO2016132233A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
WO2016134846A1 (en) 2015-02-27 2016-09-01 Rottapharm Ltd. Composition for the treatment of acne
WO2016166732A1 (en) 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
WO2017008909A1 (en) 2015-07-16 2017-01-19 Rottapharm S. P. A. Oral formulation comprising berberine and morus alba extract
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US11013747B2 (en) 2016-09-09 2021-05-25 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2019149884A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
WO2021029429A1 (en) 2019-08-13 2021-02-18 大塚製薬株式会社 Oral pharmaceutical composition
WO2021029430A1 (en) 2019-08-13 2021-02-18 大塚製薬株式会社 Oral pharmaceutical composition containing heterocyclic compound
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
US11311488B2 (en) 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
WO2021252741A1 (en) 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
EP4364738A2 (en) 2020-06-10 2024-05-08 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Similar Documents

Publication Publication Date Title
US3173876A (en) Cleaning methods and compositions
JP3001980B2 (en) Aqueous composition for rinsing shower equipment and method for keeping shower equipment clean
JP4257201B2 (en) Hard surface detergency composition containing solvent system
JP5419799B2 (en) Liquid detergent composition for floors
JP2004503661A (en) Multipurpose cleaning agent with low organic solvent content
US5415811A (en) Cleaning composition and method for utilizing same
EP0565950A1 (en) Glass cleaner having antifog properties
JPH0341200A (en) Composition for cleaning rigid surface
US2093824A (en) Detergent cloth
US5156760A (en) Surface cleaning compositions
US6720297B2 (en) Cleaning composition
JP2003171688A (en) Neutral liquid detergent composition
US2714094A (en) Ceramic surface cleanser
JPS604876B2 (en) antimicrobial aqueous solution
US1452093A (en) Method of cleansing
CN111979053A (en) Household cleaning wet tissue composition without water mark during wiping and preparation method thereof
JPH03174496A (en) Detergent composition
KR100593531B1 (en) Aqueous Glass Cleaner Composition
US3546124A (en) Cleansing solutions
JPS63309594A (en) Household cleaner composition
CA2307717C (en) Plumbing fixture surface restoration process
JP2821727B2 (en) Body wash composition
WO2000023553A1 (en) Scrub free formulation for cleaning surfaces
US1574407A (en) Cleaning composition for granite, stone, etc
JP2001026532A (en) Aqueous liquid soap composition